Prostatype Genomics
Prostatype Genomics' CEO on the road to Medicare approval in filmed company presentation
Prostatype Genomics AB announces that a filmed company presentation in which CEO Fredrik Rickman talks about the commercialization in the United States of the company's gene test Prostatype® is now available. The test was launched in the US earlier this year, and the company expects it to be included in Medicare's reimbursement system in Q4. This would enable more extensive use in the world's largest single market with annual sales of approximately SEK 2 billion.
Prostatype Genomics is conducting a preferential rights issue with subscription period until September 2, 2024 to finance commercialization activities in the United States and in selected markets in Europe.
Watch the filmed company presentation and read more about the rights issue on the company's rights issue webpage.
For further information about Prostatype Genomics, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 (0) 73 049 77 01
Email: fredrik.persson@prostatypegenomics.com
About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.
| Datum | 2024-08-27, kl 15:15 |
| Källa | MFN |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!